© Fotolia / IDNЛаборатория. Archival photo© Fotolia / IDN
The state Corporation rostec and the Russian pharmaceutical company «R-farm» will create a joint venture for the production and sale of drugs for the treatment of HIV infection, according to a press release from the companies.
«National immunobiological company», part of state Corporation rostec and the Russian pharmaceutical company «R-Pharm» has signed an agreement to establish a joint venture for the production of antiretroviral drugs. The document was signed by the head of the «national immunobiological company» Maryam Hubiev and the General Director of group of companies «R-Pharm» Vasily Ignatiev. Joint venture established for manufacture and sale of medicines for the treatment of HIV infection in Russia, the registration certificate transferred to him by the company «R-Pharm» — said in a press release.
The parties declined to disclose financial terms of the deal. It is planned that the first products of the new joint venture will be released before the end of the year.
«National immunobiological company» was established in 2013. The company is engaged in the production and supply of vaccines of the National calendar of vaccinations and other drugs.
«R-Pharm» — Russian pharmaceutical company, which has more than 45 branches and representative offices in Russia, CIS, USA, Germany, Japan, Turkey and India.
© RIA Novosti, Integratiebeleid in photomacrography HIV infection in Russia